+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 111 Pages
  • April 2023
  • GlobalData
  • Astrazeneca PLC
  • ID: 1314893
AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AstraZeneca Plc (AstraZeneca) is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

AstraZeneca Plc Key Recent Developments

  • Apr 14, 2023: AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR
  • Apr 14, 2023: ECCMID data reinforces AstraZeneca’s commitment to transform protection for the most vulnerable by advancing science in vaccines and immune therapies
  • Apr 04, 2023: HKSTP and AstraZeneca signing MOU on Strategic Collaboration
  • Mar 28, 2023: Salipro Biotech publishes research in Scientific Reports on structure-function studies for membrane proteins in collaboration with AstraZeneca

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • AstraZeneca Plc - Key Facts
  • AstraZeneca Plc - Key Employees
  • AstraZeneca Plc - Key Employee Biographies
  • AstraZeneca Plc - Major Products and Services
  • AstraZeneca Plc - History
  • AstraZeneca Plc - Company Statement
  • AstraZeneca Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • AstraZeneca Plc - Business Description
  • Product Category: Cardiovascular, Renal and Metabolism
  • Performance
  • Product Category: COVID-19
  • Performance
  • Product Category: Oncology
  • Performance
  • Product Category: Others
  • Performance
  • Product Category: Rare Diseases
  • Performance
  • Product Category: Respiratory & Immunology
  • Performance
  • Other Break-up: Collaboration Revenue
  • Overview
  • Performance
  • Other Break-up: Product Sales
  • Overview
  • Performance
  • Geographical Segment: Australia
  • Performance
  • Geographical Segment: Canada
  • Performance
  • Geographical Segment: China
  • Performance
  • Geographical Segment: France
  • Performance
  • Geographical Segment: Germany
  • Performance
  • Geographical Segment: Italy
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: Others
  • Performance
  • Geographical Segment: Spain
  • Performance
  • Geographical Segment: Sweden
  • Performance
  • Geographical Segment: The UK
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • AstraZeneca Plc - Corporate Strategy
  • AstraZeneca Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • AstraZeneca Plc - Strengths
  • AstraZeneca Plc - Weaknesses
  • AstraZeneca Plc - Opportunities
  • AstraZeneca Plc - Threats
  • AstraZeneca Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • AstraZeneca Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 14, 2023: AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR
  • Apr 14, 2023: ECCMID data reinforces AstraZeneca’s commitment to transform protection for the most vulnerable by advancing science in vaccines and immune therapies
  • Apr 04, 2023: HKSTP and AstraZeneca signing MOU on Strategic Collaboration
  • Mar 28, 2023: Salipro Biotech publishes research in Scientific Reports on structure-function studies for membrane proteins in collaboration with AstraZeneca
  • Mar 22, 2023: AstraZeneca PLC Notice of AGM
  • Mar 17, 2023: LCRF, Daiichi Sankyo and AstraZeneca enter research collaboration
  • Mar 06, 2023: Bellvitge Hospital, IDIBELL and Astrazeneca test an application that monitors heart failure using voice
  • Feb 27, 2023: Astrazeneca announces major investment in Ontario's life sciences sector
  • Feb 24, 2023: AstraZeneca signs licence deal with KYM Biosciences for ADC CMG901
  • Feb 21, 2023: AstraZeneca PLC Annual Financial Report
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • AstraZeneca Plc, Key Facts
  • AstraZeneca Plc, Key Employees
  • AstraZeneca Plc, Key Employee Biographies
  • AstraZeneca Plc, Major Products and Services
  • AstraZeneca Plc, History
  • AstraZeneca Plc, Subsidiaries
  • AstraZeneca Plc, Joint Venture
  • AstraZeneca Plc, Key Competitors
  • AstraZeneca Plc, Ratios based on current share price
  • AstraZeneca Plc, Annual Ratios
  • AstraZeneca Plc, Interim Ratios
  • AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • AstraZeneca Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • AstraZeneca Plc, Performance Chart (2018 - 2022)
  • AstraZeneca Plc, Ratio Charts
  • AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Takeda Pharmaceutical Co Ltd
  • Sanofi
  • Pfizer Inc
  • Novartis AG
  • Merck & Co Inc
  • Johnson & Johnson
  • GSK plc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Daiichi Sankyo Co Ltd
  • Bristol-Myers Squibb Co
  • Astellas Pharma Inc
  • Amgen Inc
  • AbbVie Inc
  • Merck & Co Inc
  • GSK plc
  • Daiichi Sankyo Co Ltd
  • Amgen Inc
  • Takeda Pharmaceutical Co Ltd
  • Sanofi
  • Bristol-Myers Squibb Co
  • Astellas Pharma Inc
  • AbbVie Inc
  • Pfizer Inc
  • Eli Lilly and Co
  • Celgene Corp
  • Gilead Sciences Inc
  • Shire Pharmaceuticals International UC
  • Novo Nordisk AS
  • Johnson & Johnson